Clinical Trial Update: TAURAS - T790 AURA ScreenFailure SOC Registry Study

View source ↗

Summary

The TAURAS study, a T790 AURA ScreenFailure SOC Registry trial sponsored by AstraZeneca in Non-Small Cell Lung Cancer, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Status: TERMINATED